Given the poor long-term efficacy of current treatments for NSCLC, the structural understanding from this work of how T766M-EGFR and Ex20Ins-EGFR amplify cell growth suggests a possible route for more effective therapies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.